As a result, we identified SLF2 loss as a biomarker for a subgroup of human DLBCL patients with adverse prognosis and provided direct experimental evidence that SLF2 acts as tumor suppressor. This evidence concerns the gene SLF2 and diffuse large B-cell lymphoma.